Dr. Watowich is Founder & CEO of Ridgeline Therapeutics, a Houston-based biotechnology company developing transformative drugs to treat obesity and obesity-linked diseases, age-linked muscle weakness, and traumatic joint injuries. He is an accomplished entrepreneur, inventor, educator, researcher, and developer of world-class innovative resources, including the global “DiscoveryingDengueDrugs-Together” project with IBM and the DrugDiscovery@TACC supercomputer-based drug screening portal. Among his prime interests is developing accessible drugs to treat chronic global health problems. Dr. Watowich graduated from Carleton College, received his Ph.D. in Physical Chemistry from the University of Chicago, and was a research fellow at Harvard University.